Compared to Estimates, Immunocore (IMCR) Q2 Earnings: A Look at Key Metrics

Core Insights - Immunocore Holdings PLC reported revenue of $97.96 million for the quarter ended June 2025, marking a year-over-year increase of 29.9% [1] - The earnings per share (EPS) for the same period was -$0.20, an improvement from -$0.23 a year ago [1] - The reported revenue exceeded the Zacks Consensus Estimate of $92.64 million by 5.74% [1] - The EPS also surpassed the consensus estimate of -$0.21 by 4.76% [1] Financial Performance - Immunocore's shares have returned -7.2% over the past month, while the Zacks S&P 500 composite increased by 1.2% [3] - The stock currently holds a Zacks Rank 1 (Strong Buy), suggesting potential outperformance against the broader market in the near term [3] Geographic Revenue Breakdown - Revenue from the United States was $64.09 million, exceeding the average estimate of $59.44 million from two analysts [4] - International revenue was reported at $0.84 million, significantly below the average estimate of $4.92 million from two analysts [4] - Revenue from Europe reached $33.04 million, surpassing the average estimate of $28.27 million from two analysts [4]